Life Sciences and Healthcare

Notable mergers & acquisitions in the life sciences in Q3 2017

During the third quarter of 2017, Cortellis Deals Intelligence had 122 deals added as part of its ongoing coverage of life science mergers & acquisitions (M&A) compared to 145 in Q2 this year and 124 in Q3 the previous year.   Deal activity in the third quarter from 2009 to 2017 Deal activity in the […]

Cultivating a well-trained revenue cycle workforce

Over the past year, we have seen a pattern emerge within the revenue cycle community that is inhibiting staff members from performing their duties at the highest level. When speaking with our members, we noticed a lack of consistent training for all staff on the core concepts of basic revenue cycle processes, which is frequently […]

Notable licensing deals in the biopharma industry in Q3 2017

Introduction During the third quarter of 2017, Cortellis Competitive Intelligence registered 949 new deals (excluding mergers & acquisitions) added as part of its ongoing coverage of pharmaceutical licensing activity compared to 1,007 in Q2 this year and 1,023 in Q3 the previous year. High-value deals: potentially worth $0.5 billion or more Approximately 40 high-value new […]

For the tradition-bound biopharma industry, resisting change is no longer an option

“For nearly half a century the pharmaceutical industry has lagged other industries in terms of productivity, efficiency and, some might argue, innovation,” wrote Bikash Chatterjee. “The excuse was that, as a regulated industry, any flexibility to implement improvements is limited, and compliance is of paramount importance.” Chatterjee, president and CSO of Pharmatech Associates, made these […]

Key steps forward in disease control in Sub-Saharan Africa

The author, Shyama Ghosh, recently completed a detailed study of the disease landscape in Sub-Saharan Africa. Titled “Disease control in Sub-Saharan Africa: Are we doing enough?”, the following is an excerpt.   Amid the many challenges facing Sub-Saharan Africa (SSA), there are signs of progress, as well. The RB Group, in India, noting the growth […]

Accelerating – and maintaining – drug approvals in the U.S.

Bringing a drug to market is the ultimate milestone for any pharmaceutical firm that has invested significant effort, not to mention time and resources, into developing its product. But all that work and outlay does not stop at marketing approval—this achievement must be maintained. There can be various regulatory requirements that a firm must meet […]

Advances and challenges facing the biosimilars market

The majority of the 10 top-selling drugs in 2016 were biologicals, each exceeding sales of $5 billion. With increasing pressure to reduce healthcare costs, there is a need for cheaper biologicals and thus greater demand for biosimilars, biological drugs similar to the already approved biological. The first biosimilar was approved in the EU in April […]